France Launches World’s First Blood Test That Detects 18 Early-Stage Cancers with 93% Accuracy
In a major leap for cancer diagnostics, scientists in France have developed the first blood test capable of detecting 18 different types of cancer — all in their early stages — from a single tube of blood.
The test, called OncoSeek-FR, was developed by researchers at Institut Curie and biotech firm BioMimetix. It analyzes a signature pattern of tumor-derived extracellular vesicles — microscopic particles shed by cancer cells into the bloodstream long before symptoms appear. These vesicles carry molecular fingerprints unique to different cancers, including RNA fragments, surface proteins, and lipid markers.
What sets this breakthrough apart is its machine learning–driven spectral detection platform. Instead of targeting individual mutations, the AI identifies subtle shifts in bio-patterns across thousands of vesicle features. This allows it to distinguish between cancers such as pancreatic, ovarian, lung, breast, and brain — all in Stage I — with remarkable precision.
In a clinical trial of over 11,000 participants, the test achieved 93% sensitivity for early-stage cancers, with a false-positive rate of just 0.7%. It outperformed all current multi-cancer screening tools, including methylation-based tests and protein assays.
The test takes under 20 minutes and requires no imaging or biopsies. France is already planning nationwide rollout in 2026, focusing on high-risk populations and regions with low access to advanced screening. Global partnerships are also in development to make this tool available in developing countries.
This could become the world’s first scalable, universal cancer screening test — one that catches deadly diseases before they become incurable.